This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Method Article
Surgically produced, controllable immunocompromised pigs
Eiji Kobayashi
Keio University School of Medicine
Corresponding Author
ORCiD: https://orcid.org/0000-0001-8617-3778
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Majority of research on human regenerative medicine has focused on the use of human mature cells/tissues and stem cell derived products. To ensure their safety and efficacy for clinical application, preclinical testing in large animals such as pigs, using pre-clinical and clinical matching protocols, is required. However, presently, there is no universal, stable, adjustable immunosuppressed pig model in which human regenerative cell and tissue products may be evaluated. Consequently, we established a controllable immunocompromised pig model by surgical excision of immune organs and varying the administration of immunosuppressive agents based on the physical condition and pharmacokinetic profile. Here, we describe the precise experimental procedure and provide information on immunosuppression therapies in different breeds of laboratory pigs. We provide practical information for the production of operational SCID pigs. We believe that our procedure may be immediately implemented in human-to-pig experiments, resulting in cost-benefit perspectives and furthering the development of new regenerative medicine.
Keywords
Translational research, immunosuppression, pig, transplantation
Figure 1
Figure 2
Figure 3
Figure 4
This is a list of supplementary files associated with this preprint. Click to download.
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
History
CURRENT STATUS: Posted
Version 1
Posted 03 Oct, 2019
No community comments so far
Metrics
Comments: 0
HTML Views: ...
Associated Publications
Development of an immunodeficient pig model allowing long-term accommodation of artificial human vascular tubes
by Manabu Itoh, Yosuke Mukae, Takahiro Kitsuka, +13
Nature Communications (21 May, 2019)
Learn more about our company.
This is a preprint. It has not completed peer review.
Method Article
Surgically produced, controllable immunocompromised pigs
Eiji Kobayashi
Keio University School of Medicine
Corresponding Author
ORCiD: https://orcid.org/0000-0001-8617-3778
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
History
CURRENT STATUS: Posted
Version 1
Posted 03 Oct, 2019
No community comments so far
Metrics
Comments: 0
HTML Views: ...
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Majority of research on human regenerative medicine has focused on the use of human mature cells/tissues and stem cell derived products. To ensure their safety and efficacy for clinical application, preclinical testing in large animals such as pigs, using pre-clinical and clinical matching protocols, is required. However, presently, there is no universal, stable, adjustable immunosuppressed pig model in which human regenerative cell and tissue products may be evaluated. Consequently, we established a controllable immunocompromised pig model by surgical excision of immune organs and varying the administration of immunosuppressive agents based on the physical condition and pharmacokinetic profile. Here, we describe the precise experimental procedure and provide information on immunosuppression therapies in different breeds of laboratory pigs. We provide practical information for the production of operational SCID pigs. We believe that our procedure may be immediately implemented in human-to-pig experiments, resulting in cost-benefit perspectives and furthering the development of new regenerative medicine.
Figure 1
Figure 2
Figure 3
Figure 4
Associated Publications
Development of an immunodeficient pig model allowing long-term accommodation of artificial human vascular tubes
by Manabu Itoh, Yosuke Mukae, Takahiro Kitsuka, +13
Nature Communications (21 May, 2019)